home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.17 -0.52 (-1.25%)

Streaming Delayed Price Updated: 3:38 PM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague ↗

December 16, 2022

Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.

Via The Motley Fool

Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip ↗

December 10, 2022

These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Exelixis ↗

December 09, 2022

Via Benzinga

Where Exelixis Stands With Analysts ↗

December 09, 2022

Via Benzinga

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

December 08, 2022

From Exelixis, Inc.

Via Business Wire

What 4 Analyst Ratings Have To Say About Exelixis ↗

November 02, 2022

Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:

Via Benzinga

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

December 08, 2022

From Exelixis, Inc.

Via Business Wire

3 Stocks to Buy Hand Over Fist in December ↗

December 03, 2022

These stocks could be big winners.

Via The Motley Fool

Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022

November 30, 2022

From Exelixis, Inc.

Via Business Wire

Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right ↗

November 30, 2022

Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.

Via The Motley Fool

Exelixis Inks Two Licensing Pacts For Cancer Programs ↗

November 02, 2022

Via Benzinga

Exelixis (EXEL) Q3 2022 Earnings Call Transcript ↗

November 02, 2022

EXEL earnings call for the period ending September 30, 2022.

Via The Motley Fool

The Smartest Stocks to Buy With $20 Right Now ↗

November 16, 2022

You don't need a mountain of cash to begin building wealth on Wall Street.

Via The Motley Fool

2 No-Brainer Stocks to Buy Right Now for Less than $20 ↗

November 12, 2022

These stocks are still bargain-priced but benefit from long-term trends.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

November 10, 2022

From Exelixis, Inc.

Via Business Wire

Here's Why This Growth Stock Is Already My 2022 Winner ↗

November 09, 2022

Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.

Via The Motley Fool

Looking Into Exelixis's Return On Invested Capital ↗

November 08, 2022

Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters.

Via Benzinga

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

November 03, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 01, 2022

From Exelixis, Inc.

Via Business Wire

Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip ↗

October 29, 2022

With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

2 Top Biotech Stocks to Buy for the Long Haul ↗

October 28, 2022

Both drugmakers have outperformed the market in the past year.

Via The Motley Fool

Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

October 26, 2022

From Exelixis, Inc.

Via Business Wire

Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution ↗

October 19, 2022

These stocks have low-to-no debt, and analysts see tons of upside.

Via The Motley Fool

Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022

October 18, 2022

From Exelixis, Inc.

Via Business Wire

The Smartest Stocks to Buy With $20 Right Now ↗

October 14, 2022

Cheap stocks have the ability to generate enormous, long-term profits for investors.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022 ↗

October 18, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com